skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Download whitepaper

Checkpoint inhibitors in bladder cancer, combination regimens in renal cell carcinoma (RCC) and novel anti-androgens in early prostate cancer treatment lines have demonstrated patient benefit, increasing survival times and addressing major areas of unmet need. However, payers are concerned about the potential impact of these therapies due to their high costs and sometimes extended treatment durations.

As a result, payers and health technology assessment (HTA) agencies have put these new treatments under scrutiny, with evidence requirements growing as the competition in each indication heats up.

This white paper looks at:

  • the reimbursement restrictions payers around the US and EU have placed on these high-cost therapies,
  • the changes in evidentiary and clinical trial evidence requirements, and future cost-control measures which are likely to be implemented to curb the total expenditure in these  indications.
Clinical Breakthroughs in Urological Cancers

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: